The US Microbiome Diagnostics Market was valued at $66.5 Million in 2023 and projected to reach to $134.8 Million by 2028, representing a compound annual growth rate of 15.2%. The US microbiome diagnostics market is positioned for sustained expansion as healthcare systems prioritize personalized medicine and preventive care strategies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The US microbiome diagnostics market reached $66.5 million in 2023 and is expected to grow to $134.8 million by 2028, representing a robust 15.2% CAGR driven by technological advancement and clinical adoption.
US healthcare providers are increasingly integrating microbiome diagnostics into precision medicine frameworks, enabling personalized treatment plans for patients with gastrointestinal and metabolic disorders.
Growing consumer interest in gut health and preventive wellness in the US market is fueling demand for direct-to-consumer microbiome testing kits and clinical diagnostic services.
Next-generation sequencing (NGS) and metagenomic analysis technologies are becoming more accessible and affordable in the US, lowering barriers to microbiome diagnostic adoption across healthcare settings.
| Report Metric | Details |
|---|---|
| Base Year | 2023 |
| Fastest Growing Segment | SHOTGUN METAGENOMICS (Technology) |
| Forecast Period | 2023-2028 |
| Growth Rate | CAGR of 15.5% from 2023 to 2028 |
| Largest Segment | DISEASE DIAGNOSTIC APPLICATIONS (Application) |
| Market Size Base Year (Billions) | ~USD 0.15 (2023) |
| Revenue Forecast (Billions) | ~USD 0.3 (2028) |
| Segments Covered | Product, Technology, Sample, Application, Type, End User |
6 segment dimensions are covered across the global market.
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS | 34.5 | 39.5 | 45.2 | 51.8 | 59.5 | 68.3 | 78.5 | 90.4 | 14.9 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 3.1 | 3.5 | 4 | 4.5 | 5.1 | 5.8 | 6.6 | 7.5 | 13.4 |
| RESEARCH INSTITUTES | 12.9 | 14.9 | 17.3 | 20.1 | 23.4 | 27.2 | 31.7 | 36.9 | 16.4 |
| TOTAL | 50.5 | 57.9 | 66.5 | 76.4 | 88 | 101.3 | 116.8 | 134.8 | 15.2 |
The US microbiome diagnostics market was valued at $66.5 million in 2023 and is expected to reach $134.8 million by 2028.
The US microbiome diagnostics market is growing at a compound annual growth rate (CAGR) of 15.2% from 2023 to 2028.
Key drivers in the US include increasing precision medicine adoption, rising prevalence of gastrointestinal disorders, expanding insurance reimbursement, regulatory approvals, and growing consumer awareness of microbiome health.
The US is seeing rapid adoption in gastroenterology, primary care, metabolic disease management, and infectious disease specialties, with integration into major medical center networks.
The US market growth rate of 15.2% is slightly below the global CAGR of 15.5%, but the US represents a mature, high-value market with strong clinical validation and reimbursement infrastructure.
The objective of the study is to analyze the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies’ developments such as product launches and approvals, expansions, and partnerships of the leading players, the competitive landscape of the microbiome diagnostic market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.
The four steps involved in estimating the market size are
The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the microbiome-based diagnostics market. A database of the key industry leaders was also prepared using secondary research.
The primary research data was collected after acquiring knowledge about the microbiome diagnostics market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as doctors, nurses, and hospital purchase managers) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, Rest of the World. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.
A breakdown of the primary respondents is provided below:

Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Tiers are defined based on a company’s total revenue. As of 2022: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
|
COMPANY NAME |
DESIGNATION |
|
DNA Genotek (US) |
Manager |
|
Viome Life Sciences (US) |
VP Sales |
|
Genetic Analysis AS (Norway) |
Regional Sales Head |
|
Becton, Dickinson and Company (US) |
Sales Director |
All major product manufacturers offering various microbiome diagnostics were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value microbiome-based diagnostics market was also split into various segments and subsegments at the region and country level based on:

To know about the assumptions considered for the study, Request for Free Sample Report

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the microbiome-based diagnostics industry.
Microbiom diagnostic products are used to investigate and understand the complex communities of microorganisms living in and on the human body. Microbiome diagnostics involves collecting samples from various body sites, such as the skin, gut, mouth, and other mucosal surfaces, and analyzing the genetic material such as DNA, RNA of the microorganisms within these samples.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all Microbiome Diagnostics Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report